Search form

Home
LoginSubscribe
  • Home
  • Country Intelligence
  • Industry Directory
  • Offsets / IC
  • Tenders
    • Haiti(0/week)
    • Guyana(0/week)
    • Honduras(0/week)
    • Jamaica(0/week)
    • Netherlands Antilles(0/week)
    • View all (0/week)
  • News
    • United States(1123/week)
    • Manufacturing(540/week)
    • Energy(431/week)
    • Technology(1037/week)
    • Other Manufacturing(333/week)
  • Events
  • About us
    • Who we are
    • Our People
    • Partners
    • Contact us
  • LinkedIn
  • Login
  • Twitter
  • Register
  • Home
  • News

Ibrutinib

Jun 12, 2020
EHA25Virtual: Advances in Treatment of High Risk Chronic Lymphocytic Leukemia
Apr 21, 2020
U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
Apr 21, 2020
IMBRUVICA® (ibrutinib) Receives 11th FDA Approval
Dec 10, 2019
Small Molecule Oncology Drug Market Forecast to Exceed $66 Billion in 2019
Dec 07, 2019
More than Seven-Year Analysis of Early Treatment with IMBRUVICA® (ibrutinib) Monotherapy Showed Improved Progression-Free Survival in Patients with Mantle Cell Lymphoma (MCL) that Relapsed or Were Unresponsive to Prior Regimen
Dec 07, 2019
IMBRUVICA® (ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukemia
Dec 07, 2019
Extended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® (ibrutinib) in the Treatment of Chronic Lymphocytic Leukemia (CLL)
Dec 07, 2019
IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Data Show High Rates of Disease Clearance in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
Nov 21, 2019
AbbVie to Present Latest Clinical Research in the Treatment of Leukemias, Lymphomas and Other Blood Cancers at 2019 ASH Annual Meeting
Nov 14, 2019
Ascentage Pharma to Release Updated Data of its Novel, Third-Generation BCR-ABL Inhibitor, HQP1351, in Chinese Chronic Myeloid Leukemia Patients in an Oral Presentation at the 61st American Society of Hematology Annual Meeting
Nov 08, 2019
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Nov 08, 2019
AbbVie Submits Supplemental New Drug Application to U.S. FDA For IMBRUVICA® (ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic Leukemia
Nov 08, 2019
BioInvent to Present BI-1206 Preclinical Data in Mantle Cell lymphoma at ASH 2019
Nov 06, 2019
Eli Lilly and Company to Present Multiple Abstracts for LOXO-305 at ASH 2019
Oct 09, 2019
Nordic Nanovector Presentations at the Annual Congress of the European Association of Nuclear Medicine (EANM)
Jul 12, 2019
Imbruvica (ibrutinib; AbbVie/Johnson & Johnson) Drug Overview & Product Profiles 2017-2026
Jul 08, 2019
Zanubrutinib (BeiGene) Drug Overview and Product Profiles 2017-2026
Jul 08, 2019
Calquence (acalabrutinib; AstraZeneca/Acerta) Markets, 2017-2026: A Novel, Orally Available, Second-Generation Bruton's Tyrosine Kinase Inhibitor with Potential Antineoplastic Activity
Jun 12, 2019
Tolero Pharmaceuticals Announces First Patient Dosed with Investigational Agent TP-0903 in Phase 1/2 Study in Patients with Previously Treated Chronic Lymphocytic Leukemia andSmall Lymphocytic Lymphoma
Jun 03, 2019
IMBRUVICA® (ibrutinib) Long-Term Data from Two Pivotal Phase 3 Studies at ASCO and EHA Demonstrate Sustained Efficacy and Safety in Patients with Chronic Lymphocytic Leukemia (CLL)
  •  
  • Page 1
  • ››

Latest News

Jul 17, 2025

Toshiba Releases Automotive Photorelay with 1800V Output Withstand Voltage

Jul 17, 2025

UFP Industries to Report Second Quarter 2025 Results on Monday, July 28, 2025

Jul 17, 2025

Kobelco Construction Machinery Digitally Transforms Demand and Supply Planning Capabilities With Blue Yonder...

Jul 17, 2025

Entegris to Report Results for Second Quarter of 2025 on Wednesday, July 30, 2025

Jul 17, 2025

Black Stone Minerals, L.P. Announces Distribution and Schedules Earnings Call to Discuss Second Quarter 2025...

Jul 17, 2025

NVE Schedules Conference Call on First Quarter Results

Jul 17, 2025

Power Integrations to Release Second-Quarter Financial Results on August 6

Jul 17, 2025

Merz makes first trip to London amid warming post-Brexit ties

View all News

Agenda

30
September
PortugalTroia, Portugal
Seabed Security, 30 September - 01 October 2025, Troia, Portugal
Seabed Security | 30 September - 01 October 2025 | Troia, Portugal Defence iQ Announces Inaugural Seabed Security...
23
September
United KingdomLondon, UK
Countering Explosive Threat & Demining conference, September 23 - 24, 2025, London, UK
Countering Explosive Threat & Demining conference | September 23 - 24, 2025 | London, UK The Countering Explosive...
View All Events

SUBSCRIBE

to Epicos.com
Please register in order to have access to personalized daily information on world-wide A&D industry developments and business opportunities.
Subscribe

REGISTER

for Epicos.com Newsletter
Sign up for our free newsletters and receive twice a week news and intelligence regarding the Aerospace & Defence Industry, meticulously selected by our editorial team.
Sign Up
Home
  • SIGN UP FOR NEWSLETTER
  • NEWSLETTER ARCHIVE
  • ADVERTISE WITH US
  • CONTACT US
  • PRIVACY POLICY
  • INFORMATION SECURITY POLICY
© 2025 EPICOS
Made by Wedia